Sumatriptan Succinate
PreclinicalSmall molecule
GSKSumatriptan Succinate is a small molecule that works as a Serotonin 1b (5-Ht1b) Receptor Agonist; Serotonin 1d (5-Ht1d) Receptor Agonist.[2] It is being investigated across 3 indications, with its most advanced program in Preclinical.[1]
Sumatriptan Succinate is one of 79 small molecule programs targeting Rosacea. It is currently in Preclinical.
3
Indications
18
Total Trials
0
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
63 competitors in Migraine Disorder
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Epidiolex
Jazz PharmaceuticalsApproved
Depakote
AbbVieApproved
Bayer Aspirin
BayerApproved
Revia
TevaApproved
Medrol
PfizerApproved
Elavil
AstraZenecaApproved
Rozerem
TakedaApproved
Dostinex
PfizerApproved
Nurtec
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Migraine6 trials
Show 3 more trials
Headache2 trials
Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache
Completed·—·Phase 4·NCT04257851·60 enrolled
Fasting Conditions2 trials
MPA1 trial
5 more indications
Cluster headache1 trial
Phase 11 trial
Dysmenorrhea1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sumatriptan Succinate. EMBL-EBI & Wellcome Sanger Institute.
- [4]